Zometa (Zoledronic acid) for Myeloma | MyMyelomaTeam

Connect with others who understand.

sign up Log in
About MyMyelomaTeam
Powered By

Zometa is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat people with multiple myeloma. Some doctors may also prescribe Zometa for people who have monoclonal gammopathy of undetermined significance (MGUS). Zometa may be referred to by its drug name, zoledronic acid.

Zometa is a bisphosphonate. Bisphosphonates are believed to work in cases of myeloma by reducing the activity of osteoclasts, the cells that break down bone. Bisphosphonates are believed to work by reducing the number of bone lesions, thereby improving pain and lowering the risk for fractures.

How do I take it?
Zometa is administered by intravenous (IV) infusion every three to four weeks.

Zometa comes in vials of concentrated or prepared solution.

Side effects
The FDA-approved label for Zometa lists common side effects including nausea, fatigue, anemia, bone pain, constipation, fever, vomiting, and difficulty breathing.

Rare but serious side effects listed for Zometa include kidney toxicity, osteonecrosis (death of bone tissue) in the jaw, atypical femoral (upper leg) fractures, fetal harm, hypersensitivity reactions, and severe bone, muscle, or joint pain.

For more details about this treatment, visit:

Zometa — FDA

Drug Therapy for Multiple Myeloma — American Cancer Society

Monoclonal Gammopathy of Undetermined Significance (MGUS) — Mayo Clinic

Continue with Facebook
Continue with Google
Lock Icon Your privacy is our priority. By continuing, you accept our Terms of use, and our Health Data and Privacy policies.
Already a Member? Log in